Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Third Rock Rolls

This article was originally published in Start Up

Executive Summary

Founded by a team of former Millennium Pharmaceutical executives including former CEO Mark Levin, Third Rock Ventures intends to return to the venture capital model of old. The Boston-based firm intends to start companies that can leverage a novel technology capable of creating multiple drugs for multiple diseases.
Advertisement

Related Content

Few Exits, But Lots Of Cash: Third Rock Closes $516M Third Fund
The A-List: 2008's Trend Shaping Series A Financings
The A-List: 2008's Trend Shaping Series A Financings
20% Solution: Addressing the Biotech/Pharma Logjam with Innovation Partnerships
20% Solution: Addressing the Biotech/Pharma Logjam with Innovation Partnerships
Millennium: The Risks of Forward Integration
Millennium: The Risks of Forward Integration
Millennium Makes Its Case as a Drug Developer

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC091481

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel